close image
Get-in-touch

Get in touch with us

    close image
    Get-in-touch

    Get in touch with us

      close image
      close image
      Get-in-touch

      Join us

        BLOG

        Pharma-Style Development Comes to Cosmetics

        Published: November 21, 2026 4 min. read
        cavtar

        GaiA

        Subscribe Now
        close image
        career banner glow career banner glow
        Circle-element
        Circle-element
        Circle-element
        Circle-element
        Circle-element
        Circle-element
        Circle-element

        For decades, most cosmetic products were developed by combining well-known ingredients into new textures, fragrances and formats. That is changing. A growing number of beauty companies now develop products the way pharmaceutical companies develop drugs: starting from a biological target, screening candidates systematically, testing in validated models, and proving efficacy in clinical studies.

        The shift is driven by consumers who expect visible, proven results, by the rise of dermocosmetics and “skin health” positioning, and by tighter regulation of both safety and claims.

        Who Is Doing It

        The trend spans the whole industry. Large beauty groups run dermatology-focused brands and use reconstructed human skin models in their research. Ingredient suppliers increasingly launch biotech actives, such as peptides, ferments and bio-identical molecules, with clinical data attached. And fast-growing direct-to-consumer brands have built their own biotech labs, using AI-driven screening, in vitro and ex vivo testing, and human clinical studies to develop proprietary molecules.

        Pharmaceutical Methods Making Their Way Into Beauty

        • Target-based development. Instead of starting from an ingredient, teams start from a biological mechanism, such as collagen production, barrier repair or pigmentation, and look for actives that act on it.
        • Systematic screening. Candidate ingredients are tested in high-throughput biological assays, increasingly supported by AI models that predict which candidates are worth testing.
        • Validated non-animal models. Since the EU banned animal testing for cosmetics, reconstructed skin models, ex vivo human skin and in silico methods have become the standard toolkit for efficacy and safety work.
        • Clinical evidence. Claims are backed by controlled human studies with instrumental measurements of hydration, elasticity, wrinkles or pigmentation, often against a reference product.
        • Dose and delivery. Formulators work out the effective concentration of an active and how to deliver it into the skin, using encapsulation and other delivery systems.
        • Design of experiments and quality by design. Instead of changing one variable at a time, teams use structured experimental designs to understand how ingredients and process parameters interact.
        • Pharma-grade quality and documentation. Good manufacturing practice under ISO 22716, full batch traceability, and safety documentation for the EU product information file and the US Modernization of Cosmetics Regulation Act (MoCRA).

        The Hidden Challenge: Data

        Pharmaceutical development works because every result is recorded, traceable and connected: which batch, which formula, which method, which conditions. Many cosmetics labs are not built that way. Formulas live in spreadsheets, stability data in separate files, clinical results in reports, and safety documents in shared folders.

        That is manageable when products are simple. It breaks down when a brand develops its own actives, runs clinical studies and has to defend every claim. Typical problems include:

        • Not being able to say which formula version was used in a clinical study
        • Repeating stability and compatibility work because earlier results cannot be found
        • Slow answers when regulators, retailers or partners ask for safety and claims evidence
        • Know-how that leaves when experienced formulators move on

        What a Pharma-Style Cosmetics Lab Needs

        • One connected record of raw materials, formulas and versions, batches, and every test result linked to them
        • Structured studies for stability, compatibility, preservative efficacy and clinical testing, with clear conditions and time points
        • Traceable claims, where each claim points to the formula version and study that support it
        • Reusable knowledge, so new projects start from what already worked
        • Data security, because proprietary actives and formulas are core intellectual property

        How Scieline Helps

        Scieline brings the discipline of pharmaceutical development to cosmetics and personal care R&D. It connects formula management with INCI-based raw materials, stability and compatibility studies, preservative efficacy, safety, sensory and clinical results in one platform, with full traceability from raw material lot to finished product. The Scieline Assistant lets teams ask questions about past work in plain language, grounded in their own data, patents and literature. And because Scieline runs on-premise or in a private cloud, proprietary actives and formulation know-how stay inside the company.

        Pharma-style methods are raising the bar for what a cosmetic product can prove. The companies that keep their development data just as rigorous will be the ones that bring those products to market fastest.

        right-round-element
        About banner glow

        The Latest Industry Insights

        Ready for the new pace of R&D?

        Contact Us today or Request a Demo to see Scieline in action.

        Get-in-touch

        Get in touch with us